Consent is an important consideration if introducing testing. A patient expert highlighted that people who have had a stroke often have severe cognitive impairment, may have difficulty with their ...

October 15, 2009 (San Diego, California) — In what is believed to be a first for a health system in the US, Scripps Health has announced that it is now offering patients undergoing elective stenting a ...

A new point-of-care test can rapidly identify people with a common genetic variant associated with impaired clopidogrel function. The authors claim that this is the first study to demonstrate the ...

We sought to determine the genotype frequencies for cytochrome p450 enzyme 2C19 variant alleles both in the US pan–ethnic population and various US ethnic groups and to establish the frequency of ...

The world's first bedside genetic test has been developed. Scientists reports on the use of a simple cheek swab test, the Spartan RX CYP2C19, performed by nurses at the patient's bedside. This ...

Pilot Programme Study Results underpinning NHS Implementation Guide for CYP2C19 Genotype Testing Presented at the UK Stroke Forum genedrive plc (AIM: GDR), the point of care pharmacogenetic testing ...

OTTAWA, CANADA, January 30,2025 – Genomadix (genomadix.com), a global leader in point of need precision medicine diagnostics, announced today that they have received a medical device licence (MDL) ...

LONDON - The National Health Service (NHS) has published an implementation guide for CYP2C19 genotype testing to inform clopidogrel prescribing decisions for patients who have suffered ischemic stroke ...

The 510(k) clearance allows for modification of the labeling of the previously authorized pharmacogenetics report. The Food and Drug Administration (FDA) has granted 23andMe clearance for its CYP2C19 ...